Compare Ascendis Pharma A/S (ASND) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $244.13 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 2.8× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| ASND | TTWO | |
|---|---|---|
Market Cap | $16.67B | $46.84B |
Sector | Health | Media |
52-Week High | $277.18 | $262.29 |
52-Week Low | $189.74 | $189.69 |
Enterprise Value | $17.04B | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Take-Two Interactive (TTWO) trades at $243.60, down 3.93% over 24 hours, with a bullish technical signal from moving averages and support near $240. The company reported Q1 2026 EPS of $0.80, beating estimates, but faces fundamental challenges with a net income margin of -4.79% and negative ROE of -9.04%. Recent news highlights strong GTA VI pre-orders as a key catalyst, with FY2027 net bookings guidance maintained at $8-$8.2 billion (company earnings report, August 7, 2026).
Outlook is optimistic due to GTA VI's November 2026 launch potential, but risks include high debt levels (debt-to-asset ratio of 39.87% in 2025) and consistent net losses. Analyst consensus is strongly bullish with a $300.55 price target, suggesting 23% upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
